HIMS Q1 2026 Earnings: The GLP-1 Pivot That Crushed EPS and Why It May Not Matter

Hims & Hers reported Q1 2026 earnings on May 12 and the headline numbers looked rough: an EPS miss of over 1,100%, a $33 million write-down, and the stock falling more than 9% after-hours. But the quarter was bad by design. The company deliberately exited its compounded semaglutide business to go all-in on branded GLP-1 drugs, and the early results from that bet are hard to argue with.

What Happened

In March 2026, Hims & Hers exited the compounded GLP-1 market and pivoted entirely to branded Wegovy and Zepbound. That transition triggered a $33 million write-down that devastated the EPS number: -$0.40 against a $0.04 consensus estimate. Revenue came in at $608 million, slightly below the $617 million forecast, but still up 3.8% year-over-year. The stock fell more than 9% in after-hours trading.

Key Takeaways

• HIMS fulfilled 125,000+ Wegovy shipments within 6 weeks of launch and is adding 100,000+ new weight loss subscribers per month
• Q2 revenue guidance of $680M–$700M came in well above the $643M street estimate, a midpoint beat of roughly 7%
• Full-year 2026 revenue guidance was raised to $2.8B–$3.0B (up from $2.7B–$2.9B), with profitability targeted for 2027

What It Means for Traders

The EPS miss will dominate the initial reaction, and the 9% after-hours drop reflects that. Markets tend to react to the surface-level number before the context gets priced in. But this is a case where the standard earnings framework breaks down. The write-down was a one-time, voluntary cost the company chose to absorb to remove a legal gray area around compounded GLP-1 drugs. It does not reflect operational deterioration.

What matters more for the forward thesis is the commercial ramp on branded GLP-1. Fulfilling 125,000 Wegovy shipments within the first six weeks of launch is not a soft launch metric. Adding 100,000+ new weight loss subscribers per month at their current pricing structure translates into significant recurring revenue. Record traffic and app downloads during the quarter suggest brand momentum is building, not fading, despite the controversy around exiting compounded drugs.

The raised guidance is the most important signal. A company in genuine trouble does not raise full-year revenue guidance after a rough quarter. The Q2 midpoint of $690 million against $643 million consensus is a 7.3% beat. That kind of guide raise in the middle of a pivot is a statement of operational confidence, not a defensive move.

The risk is timing and competition. Profitability is not targeted until 2027, and HIMS is spending aggressively to build the branded GLP-1 business against Novo Nordisk and Eli Lilly, both of which have far larger distribution networks and brand recognition. The $751 million cash position and $53 million in Q1 free cash flow suggest the company has the runway to execute. But there is meaningful execution risk between here and profitable scale.

How to Track a Thesis-Driven Earnings Play

Earnings plays with a complex underlying thesis (intentional write-downs, strategic pivots, guide beats hiding beneath headline misses) are exactly the situations where documentation matters most. If you bought HIMS ahead of earnings with a specific thesis, tracking whether that thesis is playing out requires more than watching the stock price.

A free account in the Financial Tech Wiz Trading Journal is a solid starting point if you want a structured way to record your earnings trade rationale before the quarter prints, with performance analytics across all your positions over time.

FAQ

Did Hims & Hers miss earnings in Q1 2026?

Yes, on the headline numbers. HIMS reported EPS of -$0.40 against a consensus estimate of $0.04, a miss of over 1,100%. Revenue of $608 million came in slightly below the $617 million estimate. However, the EPS miss was driven by a voluntary $33 million write-down tied to the company’s exit from compounded semaglutide. The miss was structural and intentional, not a reflection of underlying business deterioration.

Why did HIMS stock drop after-hours despite strong guidance?

The 9%+ after-hours decline reflects the market’s initial reaction to the headline EPS miss and the optics of a large write-down. Markets frequently reprice on headline numbers before the full context is absorbed. The company’s Q2 guide of $680M–$700M (vs. $643M consensus) and the raised full-year range of $2.8B–$3.0B represent a meaningful beat that may take time to be reflected in the stock price.

Is the Wegovy and Zepbound pivot a good long-term bet for HIMS?

The early evidence is encouraging. 125,000 Wegovy shipments in six weeks and 100,000+ new subscribers per month suggest strong demand for the branded GLP-1 offering. Whether the pivot succeeds long-term depends on HIMS’s ability to sustain subscriber growth, manage costs, and hit the 2027 profitability target. The exit from compounded drugs removes the legal overhang but puts the company in direct competition with much larger pharmaceutical distributors. The $751 million cash position and $53 million in Q1 free cash flow give the company meaningful runway to execute.